| 查看: 287 | 回复: 11 | |||
[交流]
【深容SCI写作智能体】Abstract实测
|
|||
|
【深容SCI写作智能体】Abstract实测 如需试用【深容SCI写作智能体】，请联系深容张老师：shenrongagent [https://scioriginal.com] 上月深容推出了【深容SCI写作智能体】的Method，Introduction，Discussion智能体，写作质量非常高，全部真实参考文献，深受用户欢迎。 今天介绍的Abstract写作智能体，功能相对简单，根据用户提供的正文内容，快速起草摘要，同时输出结构式摘要和一体式摘要。 1. 用户输入正文内容： 2. 检索参考同类题材的摘要格式： 3. 输出结果Abstract。 智能体的写作质量非常高： (1) Structured ABSTRACT 1) Background Signal Transducer and Activator of Transcription 2 (STAT2) is well-known for its role in type I interferon (IFN-I) signaling, which is generally considered tumor-suppressive. However, its direct role in cancer, particularly colorectal cancer (CRC), remains underexplored. Given the critical involvement of immune and cytokine networks in CRC progression, elucidating STAT2's contribution is essential. 2) Methods We analyzed TCGA-COAD datasets to assess STAT2 and IFNAR1 expression and patient survival. Human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts were generated using CRISPR\/Cas9 technology. Cell proliferation was measured in vitro using the CellTiter 96 assay. In vivo tumor growth was evaluated by subcutaneous injection of knockout and control cells into immunodeficient or immunocompetent mice. Western blot and qPCR analyses were performed to assess downstream signaling and gene expression changes. 3) Results High STAT2 expression in TCGA-COAD tumors correlated with reduced patient survival, independent of IFNAR1 levels. STAT2 deletion impaired cell proliferation and tumor growth in both human and murine models, whereas IFNAR1 deletion did not. STAT2 KO cells exhibited reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms distinct from canonical IFN-I signaling. 4) Conclusion Our study reveals that STAT2 functions as a tumor-promoting factor in CRC, acting independently of IFNAR1-mediated IFN-I signaling. Targeting STAT2 or its downstream pathways may offer a novel therapeutic strategy for mitigating CRC progression. --- (2) Integrated ABSTRACT Signal Transducer and Activator of Transcription 2 (STAT2) is a key mediator of type I interferon (IFN-I) signaling, traditionally viewed as tumor-suppressive. However, its direct role in colorectal cancer (CRC) remains poorly defined, despite the critical influence of immune and cytokine networks on disease progression. To address this gap, we analyzed TCGA-COAD datasets and found that high STAT2 expression in CRC tumors correlated with reduced patient survival, independent of IFNAR1 levels. Using CRISPR\/Cas9 technology, we generated human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts. In vitro cell proliferation assays demonstrated that STAT2 deletion significantly impaired growth, whereas IFNAR1 deletion had no effect. In vivo studies in immunodeficient and immunocompetent mice confirmed that STAT2 KO cells formed smaller tumors compared to controls, while IFNAR1 KO cells did not differ significantly from wild-type cells. Western blot and qPCR analyses revealed that STAT2 deletion reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms independent of canonical IFN-I signaling. Our study highlights STAT2 as a potential therapeutic target in CRC, offering new avenues for mitigating disease progression by targeting its pro-tumorigenic pathways. 以上这篇Abstract起草时间仅00:01:35 【深容SCI写作智能体】包括四大模块：Method智能体、Introduction智能体、Discussion智能体、Abstract智能体。 如需试用智能体，请徽售联系深容张老师：shenrongagent [https://scioriginal.com] #SCI论文 #科研 #实验 #博士 #投稿     |
回复此楼» 猜你喜欢
323求调剂
已经有6人回复
-
一志愿北京化工大学 070300 学硕 336分 求调剂
已经有4人回复
-
352求调剂
已经有3人回复
-
一志愿东华大学化学070300，求调剂
已经有8人回复
-
277材料科学与工程080500求调剂
已经有7人回复
-
317求调剂
已经有18人回复
-
293求调剂
已经有5人回复
-
280分求调剂 一志愿085802
已经有7人回复
-
0854电子信息求调剂
已经有3人回复
-
263求调剂
已经有4人回复
» 抢金币啦！回帖就可以得到:
-
青岛高校2026招生硕士研究生
+5/750
-
求购电镜上的液氮罐
+5/175
-
福建师范大学叶应祥课题组招收2026级博士研究生
+2/146
-
祈福2026国基面上项目
+5/100
-
中飞院航空锂电池团队接受硕士生调剂
+1/86
-
广东工业大学-木质纤维素高值化利用团队招博士研究生
+1/82
-
散金币，求基金中标！！
+1/60
-
Alicat 层流压差质量流量控制器在新型硅碳负极流化床的应用- 艾里卡特（Alicat）
+3/43
-
欢迎交流咨询
+1/42
-
中国科学院杭州医学研究所覃江江课题组招聘博士后
+1/30
-
南京林业大学-国家级青年人才团队 招2026级申请考核制博士（合成化学、植物化学方向）
+1/13
-
南京林业大学-国家级青年人才团队 招2026级博士、硕士（合成化学、植物化学方向）
+1/13
-
shu湘潭大学化工学院招收化工、能源动力、工程热物理相关研究生调剂
+1/9
-
中国中医科学院中医药健康产业研究所（江西中医药健康产业研究院）2026年高层次人才等
+1/7
-
宁波东方理工大学余鹏课题组2026年上海交大联培博士生、博士后、科研助理招聘
+1/7
-
[求调剂]郑州大学生物技术专业 一志愿浙大生科院340分
+1/7
-
286求调剂
+1/6
-
26年申博自荐-计算机视觉
+1/5
-
【第三轮招生】澳科大诚招2026秋全奖博士研究生（纳米医学/生物材料，3月31号截止）
+1/3
-
湘潭大学教师招聘
+1/2
简单回复
夏末末872楼
2026-01-11 18:20
回复
pheiphei2025(金币+1): 谢谢参与
1 发自小木虫手机客户端
2026-01-11 18:31
回复
jiaoxg4楼
2026-01-11 18:39
回复
pheiphei2025(金币+1): 谢谢参与
tfang5楼
2026-01-11 18:42
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 18:51
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 19:04
回复
toppaper8楼
2026-01-11 20:07
回复
XG-WUST9楼
2026-01-11 21:35
回复
pheiphei2025(金币+1): 谢谢参与
up 发自小木虫IOS客户端
psylhh10楼
2026-01-11 22:21
回复
pheiphei2025(金币+1): 谢谢参与
庚辰辛丑11楼
2026-01-12 07:28
回复
pheiphei2025(金币+1): 谢谢参与
afit88812楼
2026-01-12 11:17
回复
